Lumos Diagnostics announces a distribution partnership with Northern Diagnostics to bring the rapid FebriDx® test into Canada to facilitate the accurate diagnosis of viral and bacterial infections at the point of care.
From November 18-24, Lumos Diagnostics and partners of WHO’s World Antimicrobial Awareness Week and CDC’s Antibiotic Awareness Week will share what clinicians and patients need to know about antibiotics and the importance of using antibiotics wisely in both community and healthcare settings.
New Study Highlights the Utility of the FebriDx® Test for Rapid Triage and Identification of COVID-19
Lumos Diagnostics today announced the publication of a COVID-19 (SARS-CoV-2) clinical trial in The International Journal of Clinical Practice. Kettering General Hospital in the UK prospectively performed a clinical assessment of the FebriDx® point-of-care (POC) fingerstick blood test to rapidly assess and differentiate viral from bacterial symptomatic respiratory infections. The study concluded that FebriDx could be deployed as part of a reliable triage strategy for identifying symptomatic cases as possible COVID-19 in the pandemic.
FebriDx® Test Featured in UK National Institute for Health and Care Excellence (NICE) Medtech Innovation Briefing (MIB)
Lumos Diagnostics rapid point-of-care (POC) FebriDx® test was featured in a Medtech Innovation Briefing (MIB), as part of the United Kingdom’s National Institute for Health and Care Excellence (NICE) guidance for the COVID-19 pandemic response. This MIB addresses the impact that the FebriDx test can have on the concurrent COVID-19 pandemic and antimicrobial resistance global health crises.
A new study in the Journal of Infection by Dr. Tristan Clark, et al. titled "Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19" identifies the FebriDx® test as a rapid, highly accurate, and affordable 'front door triage tool' to help healthcare providers differentiate viral from bacterial infection in patients with suspected COVID-19.
A peer-reviewed article just published in the Annals of Medicine titled "Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic" describes an algorithm for sustainable testing capacity to efficiently evaluate patients in response to a pandemic.
A new study just published in the Journal of Medical Economics found that the FebriDx® test could save the UK healthcare system up to £89 million a year on unnecessary antibiotics, and further its efforts in the fight against antimicrobial resistance.
Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.